Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 8/20 | 0.44 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2363776 | 0.93 | PTGES (0.42) | PTGESHSD17B13ADORA2ALMNASLC40A1 | |
| SCHEMBL2683837 | 0.92 | PTGES (0.44) | PTGESHSD17B13ADORA2ALMNASLC40A1 | |
| SCHEMBL2363909 | 0.91 | PTGES (0.49) | PTGESHSD17B13ADORA2ALMNASLC40A1 | |
| SCHEMBL10173624 | 0.89 | PTGES (0.47) | PTGESHSD17B13LMNAP2RX7 | |
| SCHEMBL2363092 | 0.85 | PTGES (0.42) | PTGESHSD17B13ADORA2ALMNASLC40A1 | |
| SCHEMBL10173617 | 0.84 | PTGES (0.52) | PTGESHSD17B13ADORA2ALMNA | |
| SCHEMBL2687806 | 0.84 | PTGES (0.49) | PTGESHSD17B13ADORA2ALMNASLC40A1 | |
| SCHEMBL1966319 | 0.83 | PTGES (0.46) | PTGESHSD17B13ADORA2ASLC40A1 | |
| SCHEMBL10173627 | 0.83 | CNR1 (0.39) | PTGESLMNA | |
| SCHEMBL2363941 | 0.82 | PTGES (0.42) | PTGESHSD17B13KMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703796-B2 | 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | MAP4, MAPRE2, IL4 | PTGES 132/4885HSD17B13 4740/4885ADORA2A 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.